Next-generation therapies to clear TDP-43 from the brain.
Neurodegenerative diseases such as motor neurone disease, frontotemporal dementia, Alzheimer’s, Parkinson’s, and Huntington’s have a common issue: the presence of a ‘culprit’ protein called TDP-43 in the brain. This protein is located within brain cells, making it difficult for medications to reach and effectively target.
The Florey Institute is pioneering the development of immunotherapies aimed to remove the TDP-43 protein in the hope of treating various neurodegenerative diseases. If successful, this will be the first time creating a therapy that is capable of delivering antibody genes across the central nervous system barriers into patient neurons, where they can target and suppress the problematic protein.
Hearts and Minds measures its impact across six core categories developed by the Association of Australian Medical Research Institutes. Key highlights include:
This project will support larger research initiatives, representing a significant step towards developing more effective treatments for various neurodegenerative diseases.
Funding support from Hearts and Minds Investments, as nominated by Core Fund Manager, Caledonia.
This content was last updated in July 2024, for further information and updates, visit The Florey.